While there is no definitive test to diagnose insomnia, your physician will work to determine the underlying cause by conducting a medical history and physical examination. You should see a doctor if sleep difficulties are disrupting your well-being. They might have trouble concentrating and be more accident prone. People with insomnia will likely be tired during the day, and may also be irritable, depressed, or anxious. The most common symptoms are difficulty falling asleep at night, waking up during the night, waking up too early, and not feeling rested in the morning. Roughly 40 million Americans experience insomnia each year. Menstruation, pregnancy, and menopause put women at a higher risk of insomnia.Īging can also contribute to insomnia, as sleep cycles change and older adultsīecome more susceptible to sleep interruptions. Be sure to alert yourĭoctor of any medications you are taking. List of prescriptions that can lead to trouble sleeping. High blood pressure medicine and birth control are among a long Or work schedule that disrupts your body’s internal clock can also lead toĬause insomnia. Health issues, including depression, contribute to sleeping problems. Or the death of a loved one, can make sleeping difficult. That interfere with sleep can cause insomnia. While insomnia may be extremely disruptive to your life, it is also highly treatable and your team at UTHealth Neurosciences will work diligently to create a personalized plan to help get you sleeping well again. Chronic insomnia is less commonĪnd is often the side effect of another problem, according to the National Three nights a week for three months or longer. Insomnia can be short term or chronic, meaning it happens at least InsomniaĬan also be caused by anxiety or depression. That may contribute to insomnia include allergies, reflux, and pain disorders. It can be triggered by physical, mental, or lifestyle problems. Is defined as a difficulty falling asleep, staying asleep, or returning to The booming multi-billion dollar sleep-health economy is an answer to the increasing number of insomnia cases, eventually opening an array of beneficial market opportunities for both private and consumer-oriented pharmaceutical companies, manufacturers, retailers, and health service providers.Insomnia, the most common sleeping problem in the United States,
Insomnia treatments series#
This would eventually create a series of opportunities for leading manufacturers, planning to expand in these regional markets and attain higher market shares.Īn expanding undiagnosed insomnia patient pool suggests that there is a clinically significant level of insomnia among global population, which prompts at the critical need for improved recognition, diagnosis, and treatment.Īccording to the research, billions are being spent on sound sleep. Request Customization Developing economies to present attractive markets sizeable patient pool with undiagnosed insomnia to pave the way for opportunitiesĭeveloping countries such as China and India are expected to witness a growth in demand for healthcare facilities and sleep aids over the next few years. Some other therapies used for the treatment of insomnia include Stimulus control therapy (SCT), Sleep-restriction therapy (SRT), Relaxation therapy, and Sleep hygiene and education (SHE). To treat chronic insomnia, cognitive behavioral therapy for insomnia (CBT-I) is also found to be a highly effective therapy, especially for older adults.
Several unique pharmacological categories, including neurokinin1 receptor antagonist, 5-HT1A agonist, 5-HT6 antagonist, H3 agonists, corticotropin-releasing hormone antagonists, cytokines, glutamatergic antagonists, and adenosine enhancers, are being investigated in order to introduce improved treatments to the market, in near future. OTC drugs are expected to represent the maximum share of the market revenue through 2026.Īs the need for improved treatment is increasing, leading pharmaceutical companies are focusing more on conducting vigorous research to find newer treatments. Commonly, OTC sleep aid such as natrol melatonin and unisom sleep gel that has minimum side effects dominate the global insomnia treatment market. Majorly, this factor will increase the demand for OTC insomnia therapeutic, since this population base is more susceptible to sleep deprivation. According to United Nations, population in the age group of 60 years and above is projected to grow by 56% by 2030, which indicates that there is a growing geriatric population. Millions of people are suffering from sleep-related disorders, and a majority of them have been preferring the OTC sleep medicines. Increasing consumption of OTC drugs & new innovations to fuel the market growth Boehringer Ingelheim International GmbH.
0 kommentar(er)
